Merck winds down Phase 3 TIGIT/PD-1 combo study due to safety-related dropouts
A large number of patient dropouts caused by immune side effects have forced Merck to end a late-stage trial of its anti-TIGIT drug vibostolimab in skin cancer. Because of the dropouts, Merck unblinded...
View ArticleCytokinetics lifts curtain on Phase 3 aficamten data, commercial launch prep...
Cytokinetics detailed results on Monday from a late-stage trial of aficamten for a rare heart disease, and the company is already hiring medical affairs and payer interaction staff as it prepares for a...
View ArticleDeciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail...
Plus, news about OnKure: Deciphera’s other bidder: Before its acquisition by Ono Pharmaceutical, Deciphera had one other bidder that offered $19.00 per share, according to a new SEC filing. In total,...
View ArticleClik here to view.
Cardurion touts Phase 2 data for PDE9 inhibitor in heart failure, plans for...
Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, three years after the Massachusetts biotech scored a $300 million investment...
View ArticleClik here to view.
Novo clears Phase 3 hemophilia A trial, plans to submit application by year's...
Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study in patients with hemophilia A, meaning patients had fewer bleeding episodes....
View ArticleSize of 340B market triples since 2018 and may double again, report says
The battle between pharma companies and hospitals over the federal drug discount program known as 340B is gaining steam as its size has tripled since 2018 and may even double again, according to a new...
View ArticleClik here to view.
Shionogi misses primary endpoint in Phase 3 for Covid-19 antiviral
Shionogi’s once-daily Covid-19 antiviral ensitrelvir missed the primary endpoint in a Phase 3 study, two months after scoring full approval in Japan. In the NIH-partnered SCORPIO-HR study, ensitrelvir...
View ArticleClik here to view.
WHO members miss deadline for pandemic accord draft, will continue talks
Member countries of the World Health Organization said they failed to agree on a draft of a long-awaited pandemic agreement by a deadline last week, but the group will continue talks ahead of a major...
View ArticleAbbVie goes deeper into neuroscience with collaboration worth as much as $2B
In its next big neuro deal, AbbVie is betting $65 million — and another $1.95 billion in potential payments — on a platform that aims to achieve the efficacy of psychedelic compounds with fewer side...
View ArticlePfizer submits trademark application that suggests it could be launching a...
Pfizer may be the next pharma giant to launch a direct-to-consumer platform. The company applied in April to trademark “Pfizer for All” for a number of uses, including online retail pharmacy services...
View ArticleAmazon veteran Missy Krasner shares why now is the time for young health...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) If you want to get a pulse on digital health, Missy Krasner is an excellent person to ask. For the last...
View ArticleClik here to view.
Exclusive: AstraZeneca, BMS and Takeda partner with Harvard startup using AI...
Nabla Bio, a small startup founded by scientists from geneticist George Church’s lab at Harvard Medical School, has formed drug discovery collaborations with AstraZeneca, Bristol Myers Squibb and...
View ArticleNovo Nordisk reports four-year weight loss data on Wegovy
In a new analysis of Novo Nordisk’s vast SELECT study, researchers may have a better answer for one of the biggest questions surrounding GLP-1s — how long can the weight loss last? Among trial...
View ArticleBayer cuts 1,500 staffers companywide in campaign to reduce bureaucracy
More details have started to emerge on how exactly Bayer is executing its broader company restructuring. The German conglomerate disclosed that 1,500 full-time employees had been laid off across...
View ArticleClik here to view.
The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer...
Siddhartha Mukherjee is something of a biotech Renaissance man. First and foremost, he sees himself as an oncologist. But that core interest has led him in many directions, including running a research...
View ArticleAllogene's $110M offering; Apellis refinances
Plus, news about FogPharma, Artbio, Enveric, MindBio and Allozymes: Allogene taps investors for $110M: The biotech priced a common stock offering that included mutual funds, institutional investors and...
View ArticleClik here to view.
Updated: Sands Capital raises $555M for third life sciences fund
Sands Capital said Tuesday it closed a $555 million life sciences fund, marking its third fund in the industry. The Arlington, VA-based long-term investor will devote the Pulse III fund to drug...
View ArticlePliant touts additional Phase 2a data for oral IPF drug that’s already in a...
Pliant Therapeutics unveiled more efficacy data from a small mid-stage trial of its lead candidate in idiopathic pulmonary fibrosis, which shows that its oral drug could potentially reverse fibrosis....
View ArticleWuXi AppTec trims 'small percentage' of workers at US site as market shifts
WuXi AppTec is cutting a small number of roles at a facility in St. Paul, MN, a company spokesperson told Endpoints News in an email. “This action was taken due to a shift in market conditions over the...
View ArticleClik here to view.
FDA offers more clarity on safety testing for cell therapies
The FDA is providing sponsors of cell therapies with a new draft guidance document on the kinds of safety testing they should perform. The 14-page guidance, published late last month, provides sponsors...
View Article